Compare · CBUS vs NXTS
CBUS vs NXTS
Side-by-side comparison of Cibus Inc. (CBUS) and Nexentis Technologies Inc. (NXTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBUS and NXTS operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- CBUS is the larger of the two at $98.6M, about 97.1x NXTS ($1.0M).
- NXTS has been more active in the news (4 items in the past 4 weeks vs 1 for CBUS).
- CBUS has more recent analyst coverage (4 ratings vs 0 for NXTS).
- Company
- Cibus Inc.
- Nexentis Technologies Inc.
- Price
- -
- -
- Market cap
- $98.6M
- $1.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 1
- 4
- Recent ratings
- 4
- 0
Latest CBUS
- Cibus and Crystal Crop Protection Team Up to Improve India’s Mustard Crop
- SEC Form 10-Q filed by Cibus Inc.
- Cibus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cibus Reports Second Quarter Financial Results and Provides Business Update
- Cibus to Report Second Quarter 2026 Financial Results on August 13, 2026 After the Market Close and Host Conference Call
- SEC Form S-8 filed by Cibus Inc.
- SEC Form S-8 filed by Cibus Inc.
- Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus
- CEO Wichner Craig was granted 894,309 shares (SEC Form 4)
- Cibus Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Latest NXTS
- Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis
- Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud
- SEC Form 8-K filed by Nexentis Technologies Inc.
- SEC Form PRE 14A filed by Nexentis Technologies Inc.
- Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
- Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery
- Nexentis Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-Q filed by Nexentis Technologies Inc.
- Nexentis Technologies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign